易瑞沙治疗晚期非小细胞肺癌临床观察  

The clinical observations of NSCLC patients in advanced stage receiving IRESSA therapy

作　　者：刘英杰[1] 郑有合[1] 肖益平[1] 张春盈[1] 罗淼[1] 郑晓伟[1] 邢永民[1] 

机构地区：[1]解放军第152中心医院肿瘤中心,河南平顶山467000

出　　处：《医学信息（医药版）》2010年第1期22-23,共2页

摘　　要：目的：观察易瑞沙治疗晚期非小细胞肺癌的疗效与不良反应。方法：23-N经组织学或细胞学证实的晚期非小细胞肺癌不能耐受化疗患者，初治4例，复治19例，易瑞沙口服，250mg／天，观察生存期和副作用。结果：所有患者均可进行疗效评价，不良反应如实记录。PR7例（30．43％），SD9例（39．13％），PD7例（30．43％）。总有效率（CR＋PR）69．57％；不良反应主要为皮疹、皮肤瘙痒和腹泻。结论：易瑞沙对大部分晚期非小细胞肺癌治疗有效，不良反应可耐受。Objective To observe the curative and adverse effect on NSCLC patients in advanced stage receiving IRESSA therapy. Methods 23 patients were proved to be NSCLC in advanced stage by histology or cytology, chemotherapy can＇t be tolerated, 4 of them were initial treatment, 19 patients retreatment, oral administration, 250mg/d, life span and adverse reaction were observed. Result All the therapeutic effects could be evaluated, side effects were recorded by fact. PR 7 cases （30.43%） , SD 9 cases （39.13%） , PD7 cases（30.43%）.Total effective rate （CR＋PR） 69.57%. Main adverse effects are erythra, itch of skin and diarrhea. Conclusion Iressa is effective for the most of the patients with NSCLC, side effects could be tolerated.

关 键 词：易瑞沙 非小细胞肺癌 总生存期 副作用 

分 类 号：R734.2[医药卫生—肿瘤]